This podcast discusses new data pertaining to glucagon-like peptide-1 receptor agonists in the treatment of diabetes and their cardioprotective properties. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the results of the ELIXA trial (Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 [Lixisenatide]) will prepare you to better treat your patients.